The strategic collaboration between Cipla and SIGA will provide the Biomedical Advanced Research and Development Authority (BARDA), a U.S. Department of Health and Human Services (HHS) department, with solutions for its biothreat and public health needs, said Garrett Ingram, CEO of Cipla Therapeutics and added AMR is a global priority for Cipla and our continued investment in this area along with SIGA's drug development and US experience creates a unique and strong partnership.
The World Health Organization has declared that anti-microbial resistance (AMR) one of the top 10 global public health threats facing humanity which puts at risk the effective prevention and treatment of a wide range of infections.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content